您当前所在的位置:首页 > 产品中心 > 产品详细信息
139264-17-8 分子结构
点击图片或这里关闭

(4R)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one

ChemBase编号:200
分子式:C16H21N3O2
平均质量:287.35684
单一同位素质量:287.16337693
SMILES和InChIs

SMILES:
O1C[C@H](NC1=O)Cc1cc2c(CCN(C)C)c[nH]c2cc1
Canonical SMILES:
CN(CCc1c[nH]c2c1cc(C[C@@H]1COC(=O)N1)cc2)C
InChI:
InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m1/s1
InChIKey:
ULSDMUVEXKOYBU-CYBMUJFWSA-N

引用这个纪录

CBID:200 http://www.chembase.cn/molecule-200.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
(4R)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one
IUPAC传统名
zolmitriptan
商标名
Zomig
Zomigon
AscoTop
Zomig Rapimelt
别名
ZMT
zolmitriptan
Zolmitriptan
CAS号
139264-17-8
PubChem SID
160963663
PubChem CID
441240

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID
DrugBank DB00315 external link
PubChem 441240 external link
数据来源 数据ID 价格

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 13.002183  质子受体
质子供体 LogD (pH = 5.5) -1.3495891 
LogD (pH = 7.4) -0.08771248  Log P 2.0428753 
摩尔折射率 82.4392 cm3 极化性 32.885002 Å3
极化表面积 57.36 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P 2.25  LOG S -3.18 
溶解度 1.90e-01 g/l 

分子性质

分子性质

理化性质 生物活性(PubChem)
疏水性(logP)
1.6 expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank
DrugBank -  DB00315 external link
Item Information
Drug Groups approved; investigational
Description Zolmitriptan is a synthetic tryptamine derivative and appears as a white powder that is readily soluble in water. [Wikipedia]
Indication For the acute treatment of adult migraine with or without auras.
Pharmacology Zolmitriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptors. It is structurally and pharmacologically related to other selective 5-HT1B/1D receptor agonists, and has only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Zolmitriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Zolmitriptan in humans.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic. There have been three metabolites identified: indole acetic acid, N -oxide, and N-desmethyl metabolites. However, the N-desmethyl is the only active metabolite.
Absorption Mean absolute oral bioavailability is approximately 40%. Food has no affect on the rate and extent of absorption.
Half Life The mean elimination half-life of zolmitriptan and of the active N-desmethyl metabolite is 3 hours.
Protein Binding 25%
Distribution * 8.4±3.3 L/kg
Clearance * 25.9 mL/min/kg
References
Pascual J: [Mechanism of action of zolmitriptan] Neurologia. 1998 Oct;13 Suppl 2:9-15. [Pubmed]
Martin GR: Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 Oct;17 Suppl 18:4-14. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Pascual J: [Mechanism of action of zolmitriptan] Neurologia. 1998 Oct;13 Suppl 2:9-15. Pubmed
  • Martin GR: Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 Oct;17 Suppl 18:4-14. Pubmed
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle